The global cancer
biomarkers market foreseen to grow by 13.7%, from USD 11.48 Billion in 2021 to
USD 32.06 Billion in 2029. Rising
technological advancements in the development of cancer biomarkers and
increasing use of cancer biomarkers in drug discovery & development are
foreseen to propel the market growth over the forecasted period. However,
specialised problems associated with sample collection and storage, high
capital investments, and extensive timelines for the development of cancer
biomarkers remain factors that hinder the market's growth.
Market Definition
What is Cancer Biomarkers?
Biological molecules
produced by the body or tumour in a person with cancer are known as cancer
biomarkers. Biomarkers can be of different types, such as DNA and RNA, specific
to the tumour and help to characterize alterations in the tumour.
Market Overview
The
cancer biomarkers market search study helps to thoroughly understand the
current trend in the market competitive analysis of the players in the emerging
market. Moreover, the DRO in the cancer biomarkers market offers valuable
perspicuity and a current scenario for making the right decision. The research
study covers the eminent players in the market with a detailed analysis of the
company and a financial overview containing their net sales, business mix and
geographical reach It mainly focuses on the key developments of the
products/services offered by the company in recent years. Besides, we at
Zettabyte have the expertise to analyses the global cancer biomarkers market player's
competitive landscape helping the client comprehend their specific strategic
growth approaches.
cancer
biomarkers market study by "Zettabyte Analytics" offers details about
the market scope, market segmentation, technological advancement in the cancer
biomarkers market and highlights the optimistic, competitive landscape and
trends enduring over the years.
Major players in the
cancer biomarkers market Abbott Laboratories, Agilent Technologies, Asuragen,
Inc., Becton Dickinson And Company, BIOMÉRIEUX, Bio-Rad Laboratories, Inc,
Biovision Inc., Bristol-Myers Squibb Company, Centogene N.V., Exact Sciences
Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc.,
Invivoscribe, Inc., Key Strategic Moves And Developments306, Merck Kgaa, Meso
Scale Diagnostics, Llc, Myriad Genetics, Inc., Olink , Perkinelmer, Inc.,
Qiagen N.V., Quest Diagnostics, R&D Systems, Inc., Seegene Technologies,
Inc., Siemens AG, Siemens Healthineers, Sysmex Corporation, Thermo Fisher
Scientific Inc.
COVID-19 Impact on Global Cancer
Biomarkers Market
The global impact
of COVID-19 has lost millions of lives with a massive cost to the healthcare
system. Moreover, the treatment cost for patients with COVID-19 has also had a
financial impact globally. The impact of COVID-19 on the Cancer biomarkers
market has forced the companies to change their sourcing, pricing, and
promotion strategies. The Cancer biomarkers market players are seen focusing
more on optimizing the E-commerce networks with the rising innovations in the
digital sector, which are creating new business models for the healthcare
industry player.
Research Scope
The report
provides market value for the base year 2021 and a yearly forecast from 2022 to
2029 in revenue (USD Million/ Billion). The market for each segment is present
in North America, Europe, Asia Pacific, Latin America, Middle East &
Africa, and the regional basis for the forecast mentioned above.
Key industry
dynamics, regulatory scenarios, major material dynamics and cancer biomarkers
market future markets are analyzed to understand their impact on demand for the
forecast period. Growth rates have been estimated using correlation, regression
and time-series analysis.
Market Segmentation
For the purpose
of this report, the global cancer biomarkers market segmented on the basis of biomarkers
type, cancer type, profiling technologies, application, and region:
Biomarkers
Type
|
Genetic
Biomarkers
|
Protein
Biomarkers
|
Other
Cancer Biomarkers
|
|
|
Cancer
Type
|
Bladder
Cancer
|
Breast
Cancer
|
Colorectal
Cancer
|
Kidney
Cancer
|
Leukemia
|
Lung
Cancer
|
Melanoma
|
Non-Hodgkin's
Lymphoma
|
Prostate
Cancer
|
Thyroid
Cancer
|
|
|
Profiling
Technologies
|
Bioinformatics
|
Cytogenetics
|
Imaging
Technologies
|
Immunoassay
|
Omics
Technologies
|
|
|
Application
|
Diagnostics
|
Prognostics
|
Research
& Development
|
Risk
Assessment
|
Other
Applications
|
Biomarkers Type Outlook:
On the basis of
biomarkers type, the market is segmented into genetic biomarkers, protein
biomarkers, other cancer biomarkers.
Figure 1 Cancer Biomarkers Market By Biomarkers
Type (Market Size And Forecast By Value - USD Million, 2021 & 2029)

Cancer Type Outlook:
On the basis of
cancer type, the market is segmented into bladder cancer, breast cancer,
colorectal cancer, kidney cancer, leukemia, lung cancer, melanoma,
non-hodgkin's lymphoma prostate cancer, thyroid cancer.
Figure 2 Cancer Outlook (Revenue, USD
Million, 2021)